Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.
Garrett R Ainslie, Kristina K Wolf, Yingxin Li, Elizabeth A Connolly, Yolanda V Scarlett, J Heyward Hull, Mary F Paine
文献索引:J. Pharmacol. Exp. Ther. 351(3) , 576-84, (2014)
全文:HTML全文
摘要
Dietary substances, including herbal products and citrus juices, can perpetrate interactions with conventional medications. Regulatory guidances for dietary substance-drug interaction assessment are lacking. This deficiency is due in part to challenges unique to dietary substances, a lack of requisite human-derived data, and limited jurisdiction. An in vitro-in vivo extrapolation (IVIVE) approach to help address some of these hurdles was evaluated using the exemplar dietary substance grapefruit juice (GFJ), the candidate marker constituent 6',7'-dihydroxybergamottin (DHB), and the purported victim drug loperamide. First, the GFJ-loperamide interaction was assessed in 16 healthy volunteers. Loperamide (16 mg) was administered with 240 ml of water or GFJ; plasma was collected from 0 to 72 hours. Relative to water, GFJ increased the geometric mean loperamide area under the plasma concentration-time curve (AUC) significantly (1.7-fold). Second, the mechanism-based inhibition kinetics for DHB were recovered using human intestinal microsomes and the index CYP3A4 reaction, loperamide N-desmethylation (KI [concentration needed to achieve one-half kinact], 5.0 ± 0.9 µM; kinact [maximum inactivation rate constant], 0.38 ± 0.02 minute(-1)). These parameters were incorporated into a mechanistic static model, which predicted a 1.6-fold increase in loperamide AUC. Third, the successful IVIVE prompted further application to 15 previously reported GFJ-drug interaction studies selected according to predefined criteria. Twelve of the interactions were predicted to within the 25% predefined criterion. Results suggest that DHB could be used to predict the CYP3A4-mediated effect of GFJ. This time- and cost-effective IVIVE approach could be applied to other dietary substance-drug interactions to help prioritize new and existing drugs for more advanced (dynamic) modeling and simulation and clinical assessment. Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.
相关化合物
相关文献:
2015-01-15
[J. Ethnopharmacol. 159 , 93-101, (2014)]
2014-11-01
[J. Am. Soc. Mass Spectrom. 25(11) , 1897-907, (2014)]
2014-12-01
[Biochim. Biophys. Acta 1842(12 Pt A) , 2345-56, (2014)]
2015-02-13
[J. Chromatogr. A. 1381 , 54-63, (2015)]
2014-12-30
[Proc. Natl. Acad. Sci. U. S. A. 111(52) , 18709-14, (2014)]